Prevalence of metabolic syndrome in type 2 diabetes mellitus presenting to tertiary health care centre

Sheshrao Sakharam Chavan, Sidheshwar Virbhadraappa Birajdar, Sanjay Arun Mundhe, Ashish Kumar Jain


Background: Diabetes is a syndrome of hyperglycemia and disturbances of carbohydrate, fat and protein metabolism associated with absolute or relative deficiencies in insulin secretion. Association of metabolic abnormalities represents a highly atherogenic state promoting the formation and growth of atheroma plaques in arteries. Hyperinsulinaemia/insulin-resistance and the underlying consequences are associated with presence of cardiovascular risk factors even in the absence of diabetes. Present aim is to study the prevalence of Mets in type 2 DM.

Methods: 100 patients with known diabetes were included. Data was collected with predesigned and pretested questionnaire. Data collected was history, clinical examination and investigations like CBC, KFT, LFT and lipid profile USG abdomen.

Results: A total of 100 known type 2 diabetics were enrolled in this study. Forty-eight (48%) were females and fifty-two (52%) were males. The mean age of the study participants was 55.2 years. Seventy-seven (77%) were diagnosed to have Mets. Frequency of Mets increased with age. Risk of fatty liver in Mets was 10 times than that those with fatty liver in diabetes (odds ratio -10.65 with p<0.005). Low HDL was most frequent factor 83.11% and was equally distributed in both sexes. Hypertension was second most frequent factor 81.81% and was more prevalent in female.

Conclusions: The prevalence of the metabolic syndrome in type 2 DM is high in both genders and increases with age thus posing a potential high cardiovascular risk. The modifiable risk factors should be a focus point in the management of type 2 DM.


Cardiovascular risk factors, Diabetes mellitus type II, Metabolic syndrome

Full Text:



Dedwania PC, Gupta R. Management issues in metabolic syndrome. J Assoc Physicians India. 2006;54:797-810.

Kendall DM, Sobel BE, Coulston AM, Harmel PAL, McLean BK, Peragallo-Dittko V, et al. The insulin resistance syndrome and coronary artery disease. Coronary Artery Dis. 2003;14(4):335-48

Expert panel on detection, evaluation and treatment of high blood cholesterol in adults: executive summary of the third report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel III). JAMA. 2001;285:2486-97.

Abdul-Rahim HF, Husseini A, Bjertness E, Giacaman R, Gordon NH, Jervell J. The metabolic syndrome in the West Bank population: an urban-rural comparison. Dia Care. 2001;24:275-9.

Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, et al. Frequency of WHO-defined metabolic syndrome in European cohort and an alternative definition of an insulin resistance syndrome. Dia Metab. 2002;28:364-76.

Agrawal V, Bansal M, Mehrotra R, Hansa G, Kasliwal RR. Prevalence of metabolic syndrome and its individual components in an asymptomatic Urban North Indian Population. Indian Heart J. 2003;55: 639-44.

Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-9.

Abdul Mohsin. Frequency of the metabolic syndrome in adult type 2 diabetics presenting to Pakistan Institute of Medical Sciences. JPMA. 2007;57:235.

Surana SP. The prevalence of MetS among urban Indian diabetic patients. JAPI. 2008;56(11);865-868.

Kelliny C, William J, Riesen W, Paccaud F, Bovet P. Metabolic syndrome according to different definitions in a rapidly developing country of the African region. Cardiovascular Diabetol. 2008;7:2.

Ilanne-Parikka P, Geriksson J, Lindström J, Hämäläinen H, Keinänen-Kiukaanniemi S, Laakso M, et al. Prevalence of the metabolic syndrome and its components findings from a Finnish general population sample and the diabetes prevention study cohort. Dia Care. 2004;27(9):2135-40.

Thomas GN, Ho SY, Janus ED, Lam KS, Hedly AJ, Lam TH. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP-ATP III) prevalence of the metabolic syndrome in a Chinese population. Diabetes Res Clin Pract. 2005;67:251-7.

Alebiosu CO. Metabolic Syndrome in Subjects with Type-2 Diabetes Mellitus. J National Med Assoc. 2004;6(96);817-821.

Moghaddasifar I, Lankarani KB, Moosazadeh M. Prevalence of non-alcoholic fatty liver disease and its related factors in Iran. Christopher Day. in US BMJ. 2011;343:6891.

Dyson JK, Anstee QM, McPherson S. Frontline. Gastroenterol. 2014;5:211-8.

Chan WK, Tan AT, Vethakkan SR, Tah PC, Vijayananthan A, Goh KL. Non-alcoholic fatty liver disease in diabetics - prevalence and predictive factors in a multiracial hospital clinic population in Malaysia. Journal of Gastroenterology and Hepatology. 2013;28(8):1375-83.

Moon KW, Leem JM, Bae SS, Lee KM, Kim SH, Chae HB, et al. The Prevalence of Metabolic Syndrome in Patients with Nonalcoholic Fatty Liver Disease. Korean J Hepatol. 2004;10(3):197-206.

Peter L, Jose Tan A. Prevalence of metabolic syndrome among patients with non-alcoholic liver disease. Phil J Gastroenterol. 2006;2:14-8.